CHOP

CHOP Researchers Discover Underlying Biology Behind Fontan-Associated Liver Disease

Retrieved on: 
Wednesday, April 24, 2024
Online, Science Publishing Group, Fontan procedure, Patient, Cell, Hepatocyte, Liver disease, Inferior vena cava, Science Translational Medicine, Hope, NIH, Hospital, Blood, Tissue, Robert, CHOP, Agent handling, Heart, Wellness, MD, RNA, Medical laboratory, Doctor of Philosophy, SVRF, Activity, Survivor, Disease, Pathology, Ventricular septal defect, Fibrosis, Stasi, FC, Assistant, Biology, Children's Hospital of Philadelphia, Quality of life, Scar, Defense, Pharmaceutical industry

PHILADELPHIA, April 24, 2024 /PRNewswire/ -- As patients with congenital heart diseases live longer, researchers are attempting to understand some of the other complications they may face as they age. In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).

Key Points: 
  • In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).
  • The Fontan operation is the current standard of care for single-ventricle congenital heart disease.
  • As more patients undergo the Fontan surgery for single-ventricle congenital heart disease, FALD has become a more recognized problem.
  • Little information exists on FALD, yet it is distinct from other forms of liver disease, which is why researchers at CHOP wanted to understand the basic biology that could lead to better treatment options and improve these patients' quality of life.

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

Retrieved on: 
Tuesday, April 23, 2024
FDA, Lutetium (177Lu) oxodotreotide, Brain, Cancer, Prostate, RLT, Hospital, Food, CHOP, Breast, B cell, Somatostatin, Disease, Incidence, Patient, Lung, National Cancer Institute, Diagnosis, Children's Hospital of Philadelphia, NETS, Ageing, Pharmaceutical industry

This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs.

Key Points: 
  • This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs.
  • "Lutathera is now the very first therapy approved specifically for children with GEP-NETs, offering new hope to young patients living with this rare cancer," said Tina Deignan, Therapeutic Area Head, Oncology US.
  • NETs are a type of cancer that originates in neuroendocrine cells throughout the body and are commonly considered slow-growing malignancies1.
  • In addition, the estimated radiation absorbed dose in pediatric patients was within established organ thresholds for external beam radiation and comparable to that in adults for the approved dose.

In Celebration of National Volunteer Month, Children's Hospital of Philadelphia and The Wawa Foundation Announce Inaugural Helping Hands Community Care Challenge

Retrieved on: 
Tuesday, April 23, 2024
Volunteering, Coffee, Education, Pain, SNAP, Fear, Hope, Hospital, Housing, CHOP, LDS Family Services, National Volunteer Month, Patient, Adolescence, WIC, Family, Poverty, Therapy, Child, Assistant, Children's Hospital of Philadelphia, Anxiety, Drink, Organization

PHILADELPHIA, April 23, 2024 /PRNewswire/ -- To celebrate April as National Volunteer Month, Children's Hospital of Philadelphia (CHOP) and The Wawa Foundation, commemorating its 10th anniversary this year, have come together to announce the inaugural Helping Hands Community Care Challenge taking place on Friday, September 13. The day-long event will bring together hundreds of representatives from local companies who will participate in various volunteer programs benefiting patients and families at CHOP.

Key Points: 
  • Additionally, the well-known and beloved Wawa Coffee and Care Cart will be on-site serving attendees, sharing a marquee example of a volunteer activity at CHOP.
  • Funds raised through Helping Hands support Wawa Volunteer Services at CHOP, empowering the expansion and elevation of the volunteer program, engaging more community members and creating a ripple effect of kindness.
  • "We are thrilled to partner with CHOP to present the Helping Hands Community Care Challenge," said Maria Kalogredis, Chair of The Wawa Foundation.
  • To learn more about this inaugural event and how it will impact the community, go to helpinghands.chop.edu .

Citadel Credit Union Reinforces Commitment To The Communities It Serves Through Ongoing Initiatives Amid Continued Growth

Retrieved on: 
Tuesday, April 16, 2024
Citadel, Online, Daily Local News, Education, Credit union, CHOP, Local news, Annual report, Citadel Credit Union, Wellness, Partnership, VISTA, Retirement, FFD, Food security, Growth, Key, Online shopping

EXTON, Pa., April 16, 2024 /PRNewswire/ -- Citadel Credit Union is reinforcing its dedication to supporting the communities it serves across the Chester, Bucks, Delaware, Montgomery, Lancaster, and Philadelphia counties through ongoing community initiatives.

Key Points: 
  • EXTON, Pa., April 16, 2024 /PRNewswire/ -- Citadel Credit Union is reinforcing its dedication to supporting the communities it serves across the Chester, Bucks, Delaware, Montgomery, Lancaster, and Philadelphia counties through ongoing community initiatives.
  • Citadel employees have also been on the receiving end multiple times of VISTA Today's Millennial Superstars 40 Under 40 awards .
  • "Since joining Citadel in late 2023, I've been proud to become a part of the team's ongoing efforts to achieve growth and stability while enhancing Citadel's presence in our communities," said Bill Brown, President and CEO, Citadel Credit Union.
  • Throughout the year, Citadel continued to have strong deposit growth at 2.5% percent from the prior year.

HealthQuest Capital Welcomes Ashley McEvoy to its Advisory Board

Retrieved on: 
Tuesday, April 9, 2024
Worldwide, Growth, CHOP, IAB, Executive, SAN, McEvoy, Hospital, Ecosystem, Johnson & Johnson, Procter & Gamble, Children's Hospital of Philadelphia, Medtech, Pharmaceutical industry

SAN FRANCISCO, April 9, 2024 /PRNewswire/ -- HealthQuest Capital, a private asset firm that provides capital to transformative healthcare companies, today announced the addition of Ashley McEvoy to its Industry Advisory Board (IAB). McEvoy brings over 20 years of experience from Johnson & Johnson. This appointment will enhance HealthQuest Capital as a value-add investor for its ecosystem of portfolio companies by adding another complementary industry leader to drive progress within the healthcare space.

Key Points: 
  • SAN FRANCISCO, April 9, 2024 /PRNewswire/ -- HealthQuest Capital , a private asset firm that provides capital to transformative healthcare companies, today announced the addition of Ashley McEvoy to its Industry Advisory Board (IAB).
  • This appointment will enhance HealthQuest Capital as a value-add investor for its ecosystem of portfolio companies by adding another complementary industry leader to drive progress within the healthcare space.
  • Ashley McEvoy is the former Executive Vice President and Worldwide Chairman of Johnson & Johnson's MedTech division, Ashley oversaw a vast organization with 60,000 global employees and revenue exceeding $30 billion.
  • "The addition of Ashley McEvoy strengthens our ability to identify and support innovative healthcare companies.

Mastery Schools, Children's Hospital of Philadelphia Announce Innovative Healthcare High School to Address Local Healthcare Workforce Shortages with Support from Bloomberg Philanthropies

Retrieved on: 
Friday, April 5, 2024
Automation, TIA, Growth, Health, CHOP, Partnership, Education, School, Knowledge, Bureau, Bloomberg L.P., Comp, Poverty, Student, Bloomberg Philanthropies, Hospital, Workforce, Dream, Children's Hospital of Philadelphia, Nursing

PHILADELPHIA, April 5, 2024 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) and Mastery Schools announced today an unprecedented partnership to design a high school that will help prepare students for well-paying careers in healthcare and address local education and healthcare talent needs. Through this initiative from Bloomberg Philanthropies, Mastery Hardy Williams High School will be revamped to fully integrate healthcare career knowledge and job-training with a high-quality, well-rounded high school experience for students in Philadelphia, graduating students directly into high-demand healthcare jobs at CHOP with family-sustaining wages.

Key Points: 
  • Through this initiative from Bloomberg Philanthropies , Mastery Hardy Williams High School will be revamped to fully integrate healthcare career knowledge and job-training with a high-quality, well-rounded high school experience for students in Philadelphia, graduating students directly into high-demand healthcare jobs at CHOP with family-sustaining wages.
  • "By combining classroom learning with hands-on experience, these specialized health-care high schools will prepare students for careers with opportunities for growth and advancement.
  • Despite inflation, the labor market remains incredibly competitive, with shortages in every area from direct patient care to healthcare operations to administration.
  • Bloomberg Philanthropies' investment will support school start-up costs including personnel needs, classroom and lab renovations, and other work-based learning requirements.

Love for Liam Foundation to Host the Third Annual Liam Johnson Memorial Golf Outing & Benefit Dinner on May 10, 2024

Retrieved on: 
Tuesday, March 12, 2024
Research, Epilepsy, Friends, Love, Genetic testing, Memory, CHOP, Partnership, ENGIN, Genetics, Patient, Child, Volunteering, Family, Liam, Pharmaceutical industry

The Love for Liam Foundation was formed by Heather and Kyle Johnson in memory of Liam Johnson who was diagnosed with early infantile epileptic encephalopathy.

Key Points: 
  • The Love for Liam Foundation was formed by Heather and Kyle Johnson in memory of Liam Johnson who was diagnosed with early infantile epileptic encephalopathy.
  • Funding goes directly to the Epilepsy Neurogenetics Initiative (ENGIN) at the Children’s Hospital of Philadelphia (CHOP) where Liam was cared for.
  • In its inaugural year in 2022, The Liam Johnson Memorial Golf Outing & Benefit Dinner raised over $75,000 for ENGIN Research.
  • ENGIN continues to deliver the highest level of care and targeted treatment to epilepsy patients and families.”
    To learn more about the Love for Liam Foundation, visit the website and follow the LinkedIn page.

Children's Hospital of Philadelphia's Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment Earns Two Press Ganey Awards

Retrieved on: 
Thursday, March 28, 2024
Surgeon, SDU, CHOP, Press Ganey Associates, Patient, Periodic function, Pinnacle, MD, Birth, Senior counsel, Hospital, Heart, Excellence, CFDT, Test management, Children's Hospital of Philadelphia, Parent, Nursing

PHILADELPHIA, March 28, 2024 /PRNewswire/ -- The Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment (CFDT) at Children's Hospital of Philadelphia (CHOP) has once again received prestigious recognition from Press Ganey, a healthcare company that evaluates patient satisfaction.

Key Points: 
  • As in 2022, 2021 and 2020, the CFDT won the 2023 Pinnacle of Excellence Award®, a preeminent, competitive achievement for leading healthcare organizations.
  • Presented annually, the award applauds hospitals and health systems that consistently sustain performance year-over-year.
  • "This award underscores the team's dedication to keeping our patients and families at the forefront of every decision and treatment option."
  • The SDU is the world's first birth facility in a pediatric hospital specifically designed for healthy mothers carrying babies with known birth defects.

CHOP Researchers Find Branched Chain Amino Acid Supplementation May Aid in Concussion Recovery

Retrieved on: 
Tuesday, March 19, 2024
Online, Research, Mind, Stroke, Concussion, Assistant, CHOP, Critical Care Medicine (journal), Patient, DSM-IV codes, Journal, Anesthesiology, Leucine, Dana Foundation, Health, University, Doctor of Philosophy, MD, Human, Valine, Critical care, Adolescence, Isoleucine, Veteran, Clinical trial, BCAA, Pediatrics, Traumatic brain injury, National Institutes of Health, Hospital, Head injury, Randomized controlled trial, Safety, Ageing, HIT, Bangladesh Technical Education Board, Medicine, Children's Hospital of Philadelphia, MSCE, Dietary supplement

PHILADELPHIA, March 19, 2024 /PRNewswire/ -- In the first clinical trial of a targeted pharmacologic therapeutic for mild traumatic brain injury in pediatric patients, scientists from the Minds Matter Concussion Frontier Program at Children's Hospital of Philadelphia (CHOP) have found preliminary evidence that adolescents and young adults with concussion who take a specific formulation of branched chain amino acid (BCAA) supplements after injury experience faster symptom reduction and return to physical activity. The findings were published online by the Journal of Neurotrauma.

Key Points: 
  • The mainstay of treatment remains symptom management with temporary modification of cognitive and physical activity and over the counter medication.
  • Although active rehabilitation strategies have shown promise for improving recovery time, including aerobic, vestibular, and vision interventions, these can be time and labor intensive.
  • To date, no targeted pharmacologic intervention to improve clinical outcomes in concussion has been evaluated in humans.
  • However, prior to this study, no human studies involving adolescents and young adults have assessed the potential benefits of this formulation of BCAAs as a specific treatment to aid in concussion recovery.

Withdrawn application: Adcetris, 23/02/2024

Retrieved on: 
Wednesday, April 3, 2024
PTCL-NOS, Lymphoma, B-cell lymphoma, CHOP, Patient, PTCL, Doxorubicin, Vincristine, CHP, Cancer, Vinblastine, European Medicines Agency, CTCL, Prednisone, Lymphocyte, Agency, Clinical trial, Skin, Dacarbazine, CD30, Cyclophosphamide, Medicine

Adcetris was designated an ‘orphan medicine’ (a medicine used in rare diseases) for peripheral T cell lymphoma 21 August 2019.

Key Points: 
  • Adcetris was designated an ‘orphan medicine’ (a medicine used in rare diseases) for peripheral T cell lymphoma 21 August 2019.
  • The cytotoxic molecule then enters the cancer cells and prevents them from dividing, causing the cancer cells to die.
  • The application was withdrawn after the European Medicines Agency had evaluated the initial information from the company and had prepared questions for the company.
  • If you are in a clinical trial and need more information about your treatment, speak with your clinical trial doctor.